Redigerer REGN-COV2

'''REGN-COV2''', solgt under merkenavnet '''Ronapreve''', er et eksperimentelt legemiddel utviklet av det amerikanske [[bioteknologi]]ske selskapet [[Regeneron Pharmaceuticals]]. Det er en kunstig «antistoff''cocktail''» som tar sikte på å utvikle motstandskraft mot [[koronavirus]]et [[SARS-CoV-2]] som forårsaker [[covid-19-pandemien]].<ref>{{Cite news|last=Kelland|first=Kate|date=2020-09-14|title=Regeneron's antibody drug added to UK Recovery trial of COVID treatments|language=en|work=Reuters|url=https://uk.reuters.com/article/uk-health-coronavirus-regeneron-antibody-idUKKBN2651TR|access-date=2020-09-14|accessdate=2020-10-03|archivedate=2020-10-10|archiveurl=https://web.archive.org/web/20201010191846/https://uk.reuters.com/article/uk-health-coronavirus-regeneron-antibody-idUKKBN2651TR|url-status=yes}}</ref><ref>{{Cite web|title=Regeneron's COVID-19 Response Efforts|url=https://www.regeneron.com/covid19|access-date=2020-09-14|website=www.regeneron.com}}</ref> Den består av en blanding av to [[monoklonale antistoffer]], REGN10933 og REGN10987.<ref>{{Cite news|last=Morelle|first=Rebecca|date=2020-09-14|title=Antibody treatment to be given to Covid patients|language=en-GB|work=BBC News|url=https://www.bbc.com/news/health-54120753|access-date=2020-09-14}}</ref><ref>{{Cite journal|last=Regeneron Pharmaceuticals|date=2020-09-03|title=A Master Protocol Assessing the Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for the Treatment of Hospitalized Patients With COVID-19|url=https://clinicaltrials.gov/ct2/show/NCT04426695}}</ref> Kombinasjonen av flere antistoffer har til hensikt å forhindre [[fluktmutasjon]] (''mutational escape'').<ref>{{Cite journal|last1=Baum|first1=Alina|last2=Fulton|first2=Benjamin O.|last3=Wloga|first3=Elzbieta|last4=Copin|first4=Richard|last5=Pascal|first5=Kristen E.|last6=Russo|first6=Vincenzo|last7=Giordano|first7=Stephanie|last8=Lanza|first8=Kathryn|last9=Negron|first9=Nicole|last10=Ni|first10=Min|last11=Wei|first11=Yi|date=2020-08-21|title=Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies|url=https://science.sciencemag.org/content/369/6506/1014|journal=Science|language=en|volume=369|issue=6506|pages=1014–1018|doi=10.1126/science.abd0831|issn=0036-8075|pmid=32540904|pmc=7299283}}</ref>

REGN-COV2 ble evaluert som del av den britiske [[RECOVERY Trial]].<ref>{{Cite web|title=RECOVERY COVID-19 phase 3 trial to evaluate Regeneron's REGN-COV2 investigational antibody cocktail in the UK|url=https://www.recoverytrial.net/news/recovery-covid-19-phase-3-trial-to-evaluate-regeneron2019s-regn-cov2-investigational-antibody-cocktail-in-the-uk|access-date=2020-09-14|website=www.recoverytrial.net}}</ref>

Regeneron har en avtale med [[Hoffmann-La Roche]] om produksjon og markedsføring av REGN-COV2 utenfor [[USA]].<ref>{{Cite web|date=2020-08-19|title=Roche and Regeneron link up on a coronavirus antibody cocktail|url=https://www.cnbc.com/2020/08/19/roche-and-regeneron-link-up-on-a-coronavirus-antibody-cocktail.html|access-date=2020-09-14|website=CNBC|language=en}}</ref>

Regeneron Pharmaceuticals stilte til rådighet «en enkelt 8-grams dose av REGN-COV2» som svar på en ''«compassionate use»''-henvendelse fra presidentens leger etter at USAs president [[Donald Trump]] testet positiv for [[covid-19]].<ref>{{Cite news|last=Thomas|first=Katie|date=2020-10-02|title=President Trump Received Experimental Antibody Treatment|language=en-US|work=The New York Times|url=https://www.nytimes.com/2020/10/02/health/trump-antibody-treatment.html|access-date=2020-10-02|issn=0362-4331}}</ref>

Den 20. august 2021 er kombinasjonsmedisinen betinget tillatt i [[Storbritannia]] som ''ronapreve'',<ref>[https://www.gov.uk/government/news/first-monoclonal-antibody-treatment-for-covid-19-approved-for-use-in-the-ukFirst monoclonal antibody treatment for COVID-19 approved for use in the UK]{{Død lenke|dato=januar 2022 |bot=InternetArchiveBot }}, MHRA, 20. august 2021.</ref>  I Den Europeiske Union ble det gitt slik tillatelse den 12. november 2021.<ref>[https://www.pharmazeutische-zeitung.de/ronapreve-und-regkirona-sind-zugelassen-129401/  ''Covid-19-Antikörperpräparate: Ronapreve und Regkirona sind zugelassen''], www.pharmazeutische-zeitung.de, 2021-11-12, lest 2021-11-14}}</ref>

I desember 2021 anbefalte [[Det europeiske legemiddelbyrået]] (EMA) Ronapreve til behandling av covid-19.<ref>Vg.no, 17. desember</ref>
== Referanser ==
<references />

{{Autoritetsdata}}

[[Kategori:Medikamentbruk mot covid-19]]
[[Category:Eksperimentelle legemidler]]